Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levonorgestrel emergency contraception ovulation inhibition across BMI categories
2020-000089-41Phase 2Unknown
- Sponsor
- Foundation Consumer Healthcare
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of avatrombopag in contraception (2 arms), sponsored by Foundation Consumer Healthcare. Primary endpoint: Ovulation suppression within 5 days. Status: unknown.
02
Drugs
avatrombopag
03
Conditions
contraception
Beyond the preview
Go deeper on 2020-000089-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000089-41.